Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Phase 3 Completed
722 enrolled
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Phase 3 Completed
1,613 enrolled
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Phase 2 Completed
105 enrolled 17 charts
Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
Phase 2 Completed
45 enrolled 15 charts
BETH
Phase 3 Terminated
3,509 enrolled
Stop&Go
Phase 3 Completed
420 enrolled
TC Avastin. ICORG 08-10, V6
Phase NA Completed
106 enrolled
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
Phase 3 Unknown
1,206 enrolled 19 charts
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Phase 2 Completed
215 enrolled 13 charts
ABCSG 32
Phase 2 Completed
100 enrolled